Sugi Predict

Sugi Predict / Targets / EPHA2

EPHA2

Ephrin type-A receptor 2 · P29317 · EPHA2 on Sugi Atlas →

103,261 patent compounds predicted against EPHA2, 78,699 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL231766 SCHEMBL231766 0.79 5/20
SCHEMBL59933 SCHEMBL59933 0.79 5/20
SCHEMBL135897 SCHEMBL135897 0.66 5/20
SCHEMBL134379 SCHEMBL134379 0.63 5/20
SCHEMBL134380 SCHEMBL134380 0.63 5/20
SCHEMBL159404 SCHEMBL159404 0.61 5/20
SCHEMBL158077 SCHEMBL158077 0.57 5/20
Lithocholic Acid Lithocholic Acid (SCHEMBL28449) 1.00 4/20
Lithocholic Acid Lithocholic Acid (SCHEMBL28450) 1.00 4/20
Lithocholic Acid Lithocholic Acid (SCHEMBL75701) 1.00 4/20
SCHEMBL234334 SCHEMBL234334 1.00 4/20
Lithocholic Acid Lithocholic Acid (SCHEMBL233591) 0.92 4/20
SCHEMBL9259 SCHEMBL9259 0.77 4/20
SCHEMBL135561 SCHEMBL135561 0.74 4/20
SCHEMBL135562 SCHEMBL135562 0.74 4/20
SCHEMBL167154 SCHEMBL167154 0.72 4/20
SCHEMBL167700 SCHEMBL167700 0.72 4/20
SCHEMBL159027 SCHEMBL159027 0.70 4/20
SCHEMBL139260 SCHEMBL139260 0.69 4/20
SCHEMBL139261 SCHEMBL139261 0.69 4/20

Clinical trials — most relevant to EPHA2 by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Paclitaxel With or Without Trastuzumab in Treating Patients With or Without HER-2/Neu Breast Cancer That is Inoperable, Recurrent, or Metastatic PHASE3COMPLETED
A Study to Evaluate Safety, Efficacy, Pharmacokinetics, and Immunogenicity of Test Pertuzumab (ZRC-3277, Cadila Healthcare Ltd.,) PHASE3COMPLETED
Efficacy and Safety of Sorafenib in Advanced Renal Cell Carcinoma (RCC) PHASE3COMPLETED
Dasatinib in Treating Patients With Previously Treated Malignant Mesothelioma PHASE2COMPLETED
TORI 104 Pre-Surgical Dasatinib PHASE2WITHDRAWN
Neoadjuvant GW572016 to Treat Breast Cancer PHASE2COMPLETED
ASLAN001 in Patients With Advanced or Metastatic Cholangiocarcinoma Who Progressed on at Least 1 Line of Systemic Therapy PHASE2COMPLETED
PiCCA Study (Panitumumab in Combination With Cisplatin/Gemcitabine) PHASE2COMPLETED
Phase II Study of Vandetanib in Individuals With Kidney Cancer PHASE2COMPLETED
Definitive Radiochemotherapy Plus/Minus Cetuximab in Unresectable Locally Advanced Esophageal Cancer PHASE2COMPLETED
Postoperative EGFR-TKI Therapy forContralateral Pulmonary Nodules in Patients With EGFR-Mutant NSCLC（ARMOR2501） PHASE2RECRUITING
Ruxolitinib in Combination With Trastuzumab in Metastatic HER2 Positive Breast Cancer PHASE1/PHASE2COMPLETED
A Series of Pilot Studies to Evaluate the haemoDynamic and mEtabolic Effects oF apelIn aNd rElaxin PHASE2UNKNOWN
Safety and Efficacy of the PAINLESS Nerve Growth Factor CHF6467 in Optic Pathway Glioma (OPG) PHASE2ACTIVE_NOT_RECRUITING
sEphB4-HSA in Treating Patients With Metastatic Castration-Resistant Prostate Cancer PHASE2UNKNOWN
Study of TARCEVA (Erlotinib) as Adjuvant Treatment for Locally Advanced Head and Neck Squamous Cell Carcinoma PHASE1COMPLETED
CAR-DC Vaccine and ICIs in Local Advanced/Metastatic Solid Tumors PHASE1ACTIVE_NOT_RECRUITING
C7R-GD2.CART Cells for Patients With Relapsed or Refractory Neuroblastoma and Other GD2 Positive Cancers (GAIL-N) PHASE1ACTIVE_NOT_RECRUITING
Gemcitabine/Capecitabine/ZD6474 in Advanced Solid Tumors PHASE1COMPLETED
Ad/HER2/Neu Dendritic Cell Cancer Vaccine Testing PHASE1COMPLETED
Safety and Tolerability Study of TAK-165 in Subjects With Tumors Expressing HER2 PHASE1COMPLETED
TGW211 for Click-Cleavable Imaging in HER2-Positive Cancers. EARLY_PHASE1RECRUITING
Evaluation of HER2-targeted Therapy for Gastric Cancer and Establishment and Verification of Monitoring System nanUNKNOWN
Prospective Monocentric Clinical-biological Database nanRECRUITING
Investigation of Methylation of EGFR in the Response of the Cetuximab in Metastatic Colorectal Cancer Patients nanCOMPLETED
Pathological and Nuclear Medicine Factors for Prognosis in Lung Carcinoma nanCOMPLETED
K-RAS Oncogene Mutation in Patients With Advanced Non-Small Cell Lung Cancer Associated With Exposure to Wood Smoke and Tobacco Smoking: Therapeutic Implications nanCOMPLETED
Expression of CD19 Complex in Lymphoproliferative Disorders nanUNKNOWN
The Development of Human Immunologic Assays Specific to Folate Receptor Antigen nanUNKNOWN
Pertuzumab in First Line Treatment of HER2-positive Metastatic Breast Cancer Patients nanUNKNOWN

Related proteins — ESM-2 sequence neighbours (a EPHA2 binder may also engage these)

ProteinNameSimilarity
Q1KL86 — 1.000 Q1KL86 →
Q03145 — 1.000 Q03145 →
Q60629 — 1.000 Q60629 →
P54754 — 1.000 P54754 →
EPHA5 Ephrin type-A receptor 5 1.000 landscape →
P54757 — 1.000 P54757 →
Q91735 — 1.000 Q91735 →
P54755 — 1.000 P54755 →
Q07497 — 0.998 Q07497 →
EPHB3 Ephrin type-B receptor 3 0.997 landscape →
O42422 — 0.997 O42422 →
Q07498 — 0.997 Q07498 →
O13146 — 0.996 O13146 →
O09127 — 0.996 O09127 →
Q90344 — 0.996 Q90344 →
P54759 — 0.996 P54759 →
EPHB4 Ephrin type-B receptor 4 0.995 landscape →
O73875 — 0.995 O73875 →
O73878 — 0.995 O73878 →
EPHA6 Ephrin type-A receptor 6 0.995 landscape →
Q8CBF3 — 0.994 Q8CBF3 →
Q91694 — 0.994 Q91694 →
P09759 — 0.993 P09759 →
Q61772 — 0.993 Q61772 →
Q62413 — 0.993 Q62413 →
Q91571 — 0.993 Q91571 →
EPHA8 Ephrin type-A receptor 8 0.993 landscape →
Q91845 — 0.993 Q91845 →
EPHA7 Ephrin type-A receptor 7 0.992 landscape →
EPHA3 Ephrin type-A receptor 3 0.992 landscape →